Keyphrases
Multiple Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
66%
Chimeric Antigen Receptor T-cell Therapy
55%
Chimeric Antigen Receptor T Cells (CAR-T)
54%
Overall Survival
28%
Acute Lymphoblastic Leukemia
25%
Progression-free Survival
23%
Cell-to-cell
22%
Very Good Partial Response
21%
Radiation Therapy
20%
Hematological Malignancies
20%
Myeloma
19%
Bridging Therapy
19%
High-risk Cytogenetics
18%
MD Anderson Cancer Center
18%
Complete Response
17%
B Cells
16%
Sleeping Beauty
16%
Lenalidomide Maintenance
16%
Center Experience
16%
Therapy Utilization
16%
Focal Control
16%
Lymphoma
16%
Novel Therapies
16%
Renal Impairment
16%
Chemotherapy Alone
16%
Psychological Distress
16%
Clinical Outcomes
16%
Blinatumomab
16%
Perception of Prognosis
16%
CD19 chimeric Antigen Receptor T Cells
16%
Spinal Cord Compression
16%
Cellular Immunotherapy
16%
Autologous Transplantation
16%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
16%
Quality of Life
16%
Antigen Density
16%
Renal Disease
16%
Central Nervous System
16%
Lenalidomide
15%
Multiple Myeloma Patients
14%
Chemotherapy
14%
Pretransplant
14%
Adaptive Response
13%
Emotion-focused Coping
13%
Quality of Life Improvement
13%
Bortezomib
12%
Minimal Residual Disease
11%
POLRMT
11%
Neurotoxicity
10%
Medicine and Dentistry
Multiple Myeloma
100%
Overall Survival
50%
Progression Free Survival
45%
Malignant Neoplasm
35%
Chimeric Antigen Receptor T-Cell
33%
Autologous Hematopoietic Stem Cell Transplantation
33%
Autologous Stem Cell Transplantation
33%
Acute Lymphoblastic Leukemia
33%
Lenalidomide
29%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Radiation Therapy
20%
T Cell
20%
Transplantation
20%
Myeloma
19%
Immunotherapy
19%
Diabetes
18%
Diseases
18%
Diabetic Nephropathy
16%
Cell Transplantation
16%
Hematopoietic Cell
16%
Gene Expression
16%
Spinal Cord Compression
16%
Blinatumomab
16%
B Cell Maturation Antigen
16%
Mitochondrial Gene
16%
Central Nervous System
16%
Minimal Residual Disease
13%
Neurotoxicity
12%
Prevalence
12%
Tumor Cell
11%
Antibiotics
11%
Bortezomib
10%
Neoplasm
10%
Dexamethasone
10%
Cytokine Release Syndrome
10%
Health Expenditure
8%
Cell Therapy
7%
Bone Marrow Biopsy
6%
Proportional Hazards Model
6%
Logistic Regression Analysis
6%
Clinical Trial
6%
Urinary System
6%
Quality of Life
5%
RNA Polymerase
5%
Reactive Oxygen Species
5%
Programmed Cell Death
5%
Mitochondrial Biogenesis
5%
Univariate Analysis
5%
Multivariate Analysis
5%
Hazard Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
50%
Lenalidomide
42%
Progression Free Survival
35%
Overall Survival
35%
Chimeric Antigen Receptor
33%
Prevalence
20%
Malignant Neoplasm
20%
Neoplasm
19%
Diseases
16%
Diabetic Nephropathy
16%
Myeloma
16%
Hematologic Malignancy
16%
Pathophysiology
16%
Myelodysplastic Syndrome
16%
Dexamethasone
13%
Bortezomib
13%
Cytokine Release Syndrome
12%
Neurotoxicity
12%
Antibiotics
11%
Acute Lymphoblastic Leukemia
8%
Protein P53
7%
Proteasome Inhibitor
6%
Chemotherapy
6%
Diffuse Large B Cell Lymphoma
6%
Life Expectancy
5%
End Stage Renal Disease
5%
Diabetic Complication
5%
Transcription Factor
5%
Mouse Model
5%
Reactive Oxygen Metabolite
5%
RNA Polymerase
5%
Cerebrovascular Accident
5%
Nonhodgkin Lymphoma
5%
Burkitt's Lymphoma
5%
Obesity
5%
Heart Infarction
5%
Mitochondrial RNA
5%
